Risk of Immune Recovery Uveitis in Patients with AIDS and Cytomegalovirus Retinitis

Ophthalmology

Volumn 113, Issue 4, 2006, Pages 684-694

  Kempen, John H ^a,b   Min, Yuan I ^c   Freeman, William R ^d   Holland, Gary N ^e   Friedberg, Dorothy N ^f   Dieterich, Douglas T ^g   Jabs, Douglas A ^a,b  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b JOHNS HOPKINS BLOOMBERG SCHOOL OF PUBLIC HEALTH   (United States)

^c MEDSTAR RESEARCH INSTITUTE   (United States)

^d UNIVERSITY OF CALIFORNIA SAN DIEGO   (United States)

^e JULES STEIN EYE INSTITUTE   (United States)

^f NEW YORK UNIVERSITY SCHOOL OF MEDICINE   (United States)

^g MOUNT SINAI SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CIDOFOVIR; DNA; ANTIVIRUS AGENT; CYTOSINE; DRUG DERIVATIVE; PHOSPHONIC ACID DERIVATIVE;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ADULT; ARTICLE; BLOOD; CD4+ T LYMPHOCYTE; COHORT ANALYSIS; CONTROLLED STUDY; EPIRETINAL MEMBRANE; EYE; FEMALE; HUMAN; INFORMATION PROCESSING; INTERVIEW; MALE; MEDICAL RECORD REVIEW; OPHTHALMOLOGY; PHLEBOTOMY; PREVALENCE; PRIORITY JOURNAL; RETINA MACULA CYSTOID EDEMA; RETINITIS; RISK FACTOR; SEX DIFFERENCE; UVEITIS; VISUAL ACUITY; AIDS RELATED COMPLEX; CD4 LYMPHOCYTE COUNT; CLINICAL TRIAL; CROSS-SECTIONAL STUDY; IMMUNOLOGY; INJECTION; MULTICENTER STUDY; VITREOUS BODY;

ADULT; AIDS-RELATED OPPORTUNISTIC INFECTIONS; ANTIVIRAL AGENTS; CD4 LYMPHOCYTE COUNT; CD4-POSITIVE T-LYMPHOCYTES; CROSS-SECTIONAL STUDIES; CYTOMEGALOVIRUS RETINITIS; CYTOSINE; FEMALE; HUMANS; INJECTIONS; MALE; PHOSPHONIC ACIDS; PREVALENCE; RISK FACTORS; UVEITIS, POSTERIOR; VISUAL ACUITY; VITREOUS BODY;

EID: 33645638703     PISSN: 01616420     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ophtha.2005.10.067     Document Type: Article

References (45)

1. Hoover D.R., Peng Y., Saah A., et al. Occurrence of cytomegalovirus retinitis after human immunodeficiency virus immunosuppression. Arch Ophthalmol 114 (1996) 821-827
2. Baril L., Jouan M., Agher R., et al. Impact of highly active antiretroviral therapy on onset of Mycobacterium avium complex infection and cytomegalovirus disease in patients with AIDS. AIDS 14 (2000) 2593-2596
3. Deayton J.R., Wilson P., Sabin C.A., et al. Changes in the natural history of cytomegalovirus retinitis following the introduction of highly active antiretroviral therapy. AIDS 14 (2000) 1163-1170
4. Jacobson M.A., Stanley H., Holtzer C., et al. Natural history and outcome of new AIDS-related cytomegalovirus retinitis diagnosed in the era of highly active antiretroviral therapy. Clin Infect Dis 30 (2000) 231-233
5. Palella Jr. F.J., Delaney K.M., Moorman A.C., et al., HIV Outpatient Study Investigators. Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. N Engl J Med 338 (1998) 853-860
6. Varani S., Spezzacatena P., Manfredi R., et al. The incidence of cytomegalovirus (CMV) antigenemia and CMV disease is reduced by highly active antiretroviral therapy. Eur J Epidemiol 16 (2000) 433-437
7. Yust I., Fox Z., Burke M., et al., EuroSIDA. Retinal and extraocular cytomegalovirus end-organ disease in HIV-infected patients in Europe. a EuroSIDA study, 1994-2001. Eur J Clin Microbiol Infect Dis 23 (2004) 550-559
8. Jabs D.A., Van Natta M.L., Thorne J.E., et al., Studies of Ocular Complications of AIDS Research Group. Course of cytomegalovirus retinitis in the era of highly active antiretroviral therapy. 1. Retinitis progression. Ophthalmology 111 (2004) 2224-2231
9. Kempen J.H., Jabs D.A., Dunn J.P., et al. Retinal detachment risk in cytomegalovirus retinitis related to the acquired immunodeficiency syndrome. Arch Ophthalmol 119 (2001) 33-40
10. Jabs D.A., Van Natta M.L., Thorne J.E., et al., Studies of Ocular Complications of AIDS Research Group. Course of cytomegalovirus retinitis in the era of highly active antiretroviral therapy. 2. Second eye involvement and retinal detachment. Ophthalmology 111 (2004) 2232-2239
11. Kempen J.H., Jabs D.A., Wilson L.A., et al. Risk of vision loss in patients with cytomegalovirus retinitis and the acquired immunodeficiency syndrome. Arch Ophthalmol 121 (2003) 466-476
12. Kempen J.H., Jabs D.A., Wilson L.A., et al. Mortality risk for patients with cytomegalovirus retinitis and acquired immune deficiency syndrome. Clin Infect Dis 37 (2003) 1365-1373
13. Pauriah M., and Ong E.L. Retrospective study of CMV retinitis in patients with AIDS. Clin Microbiol Infect 6 (2000) 14-18
14. Skiest D.J., Chiller T., Chiller K., et al. Protease inhibitor therapy is associated with markedly prolonged time to relapse and improved survival in AIDS patients with cytomegalovirus retinitis. Int J STD AIDS 12 (2001) 659-664
15. Walsh J.C., Jones C.D., Barnes E.A., et al. Increasing survival in AIDS patients with cytomegalovirus retinitis treated with combination antiretroviral therapy including HIV protease inhibitors. AIDS 12 (1998) 613-618
16. Goldberg D.E., Wang H., Azen S.P., and Freeman W.R. Long term visual outcome of patients with cytomegalovirus retinitis treated with highly active antiretroviral therapy. Br J Ophthalmol 87 (2003) 853-855
17. Karavellas M.P., Lowder C.Y., Macdonald C., et al. Immune recovery vitritis associated with inactive cytomegalovirus retinitis. a new syndrome. Arch Ophthalmol 116 (1998) 169-175
18. Karavellas M.P., Plummer D.J., Macdonald J.C., et al. Incidence of immune recovery vitritis in cytomegalovirus retinitis patients following institution of successful highly active antiretroviral therapy. J Infect Dis 179 (1999) 697-700
19. Karavellas M.P., Song M., Macdonald J.C., and Freeman W.R. Long-term posterior and anterior segment complications of immune recovery uveitis associated with cytomegalovirus retinitis. Am J Ophthalmol 130 (2000) 57-64
20. Nguyen Q.D., Kempen J.H., Bolton S.G., et al. Immune recovery uveitis in patients with AIDS and cytomegalovirus retinitis after highly active antiretroviral therapy. Am J Ophthalmol 129 (2000) 634-639
21. Robinson M.R., Reed G., Csaky K.G., et al. Immune-recovery uveitis in patients with cytomegalovirus retinitis taking highly active antiretroviral therapy. Am J Ophthalmol 130 (2000) 49-56
22. Song M.K., Azen S.P., Buley A., et al. Effect of anti-cytomegalovirus therapy on the incidence of immune recovery uveitis in AIDS patients with healed cytomegalovirus retinitis. Am J Ophthalmol 136 (2003) 696-702
23. Zegans M.E., Walton R.C., Holland G.N., et al. Transient vitreous inflammatory reactions associated with combination antiretroviral therapy in patients with AIDS and cytomegalovirus retinitis. Am J Ophthalmol 125 (1998) 292-300
24. Karavellas M.P., Azen S.P., Macdonald J.C., et al. Immune recovery vitritis and uveitis in AIDS. clinical predictors, sequelae, and treatment outcomes. Retina 21 (2001) 1-9
25. Henderson H.W., and Mitchell S.M. Treatment of immune recovery vitritis with local steroids. Br J Ophthalmol 83 (1999) 540-545
26. Arevalo J.F., Mendoza A.J., and Ferretti Y. Immune recovery uveitis in AIDS patients with cytomegalovirus retinitis treated with highly active antiretroviral therapy in Venezuela. Retina 23 (2003) 495-502
27. Kosobucki B.R., Goldberg D.E., Bessho K., et al. Valganciclovir therapy for immune recovery uveitis complicated by macular edema. Am J Ophthalmol 137 (2004) 636-638
28. Jabs D.A., Van Natta M.L., Kempen J.H., et al. Characteristics of patients with cytomegalovirus retinitis in the era of highly active antiretroviral therapy. Am J Ophthalmol 133 (2002) 48-61
29. Kempen J.H., Martin B.K., Wu A.W., et al. The effect of cytomegalovirus retinitis on the quality of life of patients with AIDS in the era of highly active antiretroviral therapy. Ophthalmology 110 (2003) 987-995
30. 1993 revised classification system for HIV infection and expanded surveillance case definition for AIDS among adolescents and adults. MMWR Recomm Rep 41 RR-17 (1992) 1-19
31. Jabs D.A. Ocular manifestations of HIV infection. Trans Am Ophthalmol Soc 93 (1995) 623-683
32. Holbrook J.T., Meinert C.L., Van Natta M.L., et al., Studies of Ocular Complications of AIDS Research Group. Photographic measures of cytomegalovirus retinitis as surrogates for visual outcomes in treated patients. Arch Ophthalmol 119 (2001) 554-563
33. Holland G.N., Buhles Jr. W.C., Mastre B., Kaplan H.J., and UCLA CMV Retinopathy Study Group. A controlled retrospective study of ganciclovir treatment for cytomegalovirus retinopathy. Use of a standardized system for the assessment of disease outcome. Arch Ophthalmol 107 (1989) 1759-1766
34. Ferris III F.L., Kassoff A., Bresnick G.H., and Bailey I. New visual acuity charts for clinical research. Am J Ophthalmol 94 (1982) 91-96
35. AIDS Clinical Trials Group (ACTG). Studies of ocular complications of AIDS Foscarnet-Ganciclovir Cytomegalovirus Retinitis Trial: 1. Rationale, design, and methods. Control Clin Trials 13 (1992) 22-39
36. Ferris III F.L., and Bailey I. Standardizing the measurement of visual acuity for clinical research studies. guidelines from the Eye Care Technology Forum. Ophthalmology 103 (1996) 181-182
37. Ferris III F.L., and Sperduto R.D. Standardized illumination for visual acuity testing in clinical research. Am J Ophthalmol 94 (1982) 97-98
38. Nussenblatt R.B., and Lane H.C. Human immunodeficiency virus disease. changing patterns of intraocular inflammation. Am J Ophthalmol 125 (1998) 374-382
39. Callahan L.F., and Yelin E.H. The social and economic consequences of rheumatic disease. In: Klippel J.H., Crofford L., Stone J.H., and Weyand C.M. (Eds). Primer on the Rheumatic Diseases. 12th ed. (2001), Arthritis Foundation, Atlanta 1-4
40. Davis J.L., Taskintuna I., Freeman W.R., et al. Iritis and hypotony after treatment with intravenous cidofovir for cytomegalovirus retinitis. Arch Ophthalmol 115 (1997) 733-737
41. Studies of Ocular Complications of AIDS Research Group, AIDS Clinical Trials Group. Long-term follow-up of patients with AIDS treated with parenteral cidofovir for cytomegalovirus retinitis. the HPMPC Peripheral Cytomegalovirus Retinitis Trial. AIDS 14 (2000) 1571-1581
42. Studies of Ocular Complications of AIDS Research Group, AIDS Clinical Trials Group. The ganciclovir implant plus oral ganciclovir versus parenteral cidofovir for the treatment of cytomegalovirus retinitis in patients with acquired immunodeficiency syndrome. the Ganciclovir Cidofovir Cytomegalovirus Retinitis Trial. Am J Ophthalmol 131 (2001) 457-467
43. Whitcup S.M. Cytomegalovirus retinitis in the era of highly active antiretroviral therapy. JAMA 283 (2000) 653-657
44. Kuppermann B.D., and Holland G.N. Immune recovery uveitis. Am J Ophthalmol 130 (2000) 103-106
45. Wohl D.A., Kendall M.A., Owens S., et al. The safety of discontinuation of maintenance therapy for cytomegalovirus (CMV) retinitis and incidence of immune recovery uveitis following potent antiretroviral therapy. HIV Clin Trials 6 (2005) 136-146